Winrevair Gains Approval For Pulmonary Arterial Hypertension, But High Price Could Limit Uptake
Newly approved Winrevair has shown important benefits to PAH patients. Its high price and correspondingly limited cost-effectiveness could, however, restrain its uptake.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news
More News: Hypertension | Pharmaceuticals